Scribe Therapeutics

We're pleased to announce: 📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction 📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

#EASCongress2026 has kicked off! A late-breaking oral presentation from our CEO @BenjaminLOakes will showcase preclinical data for STX-1150, our epigenetic silencing therapy that’s designed for durable LDL-C reduction & now in the clinic. Thanks to @EASCongress for featuring it!

📰 @theheraldsun article: heraldsun.com.au/health/unbelie… 🎤 If you're at #EASCongress2026 on Monday, May 25, check out the late-breaking oral presentation by Scribe co-founder and CEO @BenjaminLOakes, highlighting our preclinical data for STX-1150: businesswire.com/news/home/2026… @EASCongress

In @theheraldsun, Dr. Stephen Nicholls of @MonashVHI, Victorian Heart Hospital, and the PI leading Scribe's clinical trial shares his perspective on our epigenetic silencing drug STX-1150 and the need for improved therapies for cardiovascular disease. Links in thread ⬇️

More details on our clinical trial and commentary from Scribe CEO @BenjaminLOakes and Principal Investigator Stephen Nicholls (@MonashVHI, Victorian Heart Hospital, @MonashUni, @MonashHealth): businesswire.com/news/home/2026… #CVD #HeartHealth #CRISPR #EpigeneticEditing

STX-1150 is designed to epigenetically silence PCSK9 in the liver and deliver sustained LDL-C reduction after a single dose without permanently altering DNA, with the goal of enabling early and durable ASCVD risk reduction in patients. Link to our full announcement below ❤️‍🩹

Announcing our first clinical trial. Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). Details🧵

♥️ How our CRISPR by Design engineering approach integrates engineering of both the XE foundation to ELXR silencing machinery to enable Scribe’s lead cardiometabolic asset for LDL-C lowering @ASGCTherapy #CRISPR #EpigeneticEditing #GeneEditing

🧬 Allosteric ELXR epigenetic silencers designed to improve specificity while still achieving potent and durable target repression ⚒️ XE gene editing engineering advancements, supported by mechanistic insights into guide potency and AI-enabled predictive modeling through DeepXE

At #ASGCT2026, we presented preclinical data highlighting the latest advances across our engineered #CRISPR technologies for epigenetic silencing and gene editing. Highlights of our three oral presentations below and in thread 🧵 businesswire.com/news/home/2026…

Two #ASGCT26 oral presentations tomorrow! 🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency 🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors

Check out our full #ASGCT26 agenda for the week here: businesswire.com/news/home/2026…

We’re kicking off #ASGCT2026 today with a workshop by co-founder & VP of External Innovation @BStaahl. Details below & more to come at @ASGCTherapy later this week! 🔹Engineering CasX from clay to clinic: lessons in precision, potency, and translatability 🕒 May 11 at 3:07 pm ET

📊At #EASCongress2026, our late-breaker will report preclinical data for STX-1150, our PCSK9-targeting epigenetic silencing therapy for LDL-C lowering. 🔗 For more details, read our press release: businesswire.com/news/home/2026…

🔬At #ASGCT2026, we'll be delivering 2 oral presentations and one workshop presentation featuring latest advances to our ELXR epigenetic silencing and X-Editor genome editing technologies, including DeepXE, our AI-enabled CRISPR design platform for predicting editing efficiency.

Next month, join us at the 2026 @ASGCTherapy Annual Meeting and @EASCongress !

Happy #DNADay26! Today, we celebrate the ongoing innovations in genetics and epigenetics that are shaping the future of human health. 🧬 At Scribe, we're committed to bringing novel #CRISPR-based genetic medicines to patients in need. Learn more at scribetx.com.

This #WorldHealthDay, we’re recognizing the importance of scientific progress in improving lives. At Scribe, that mission continues to guide our work every day to advance novel #CRISPR-based genetic medicines for patients, starting with those with cardiovascular disease.